Morgan Stanley Portfolio holdings
Morgan Stanley, founded in 1935 by Henry Sturgis Morgan and Harold Stanley as a spin-off from J.P. Morgan & Co., is a leading global financial services firm headquartered in New York City. Initially focused on investment banking, it has evolved into a diversified powerhouse offering wealth management, institutional securities, and asset management services, catering to corporations, governments, institutions, and high-net-worth individuals. With a strong presence in mergers and acquisitions, underwriting, and trading, Morgan Stanley manages billions in assets and is known for its sophisticated financial advisory services. The firm has adapted to modern markets by expanding its digital offerings and wealth management division, notably through its 2020 acquisition of E*TRADE, solidifying its position as a Wall Street titan.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$2.77B |
| 2 |
McKesson
MCK
|
+$2.38B |
| 3 |
SpaceX
SPCX
|
+$2.3B |
| 4 |
HONA
Honeywell Aerospace
HONA
|
+$2.05B |
| 5 |
Amazon
AMZN
|
+$1.37B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$5.96B |
| 2 |
iShares Russell 2000 ETF
IWM
|
+$3.11B |
| 3 |
Honeywell
HON
|
+$1.96B |
| 4 |
Salesforce
CRM
|
+$1.47B |
| 5 |
Vanguard FTSE Developed Markets ETF
VEA
|
+$775M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 26.02% |
| 2 | Technology | 24.63% |
| 3 | Financials | 9.78% |
| 4 | Healthcare | 7.32% |
| 5 | Industrials | 7.25% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
7226
Spero Therapeutics
SPRO
$68.7M
| $2.02K | ﹤0.01% |
914
-3,638
| -80% | -$9.52K |
2017 Q4
34 quarters
|
|
7227
One and One Green Technologies
YDDL
$72.8M
| $2.02K | ﹤0.01% |
1,000
-42
| -4% | -$198 |
2025 Q4
2 quarters
|
|
7228
Rallybio
RLYB
$89.2M
| $2K | ﹤0.01% |
125
-1
| -0.8% | -$13 |
2021 Q3
19 quarters
|
|
7229
Fairlead Tactical Sector ETF
TACK
$291M
| $1.98K | ﹤0.01% |
62
-220
| -78% | -$6.84K |
2023 Q4
10 quarters
|
|
7230
ALPS Electrification Infrastructure ETF
ELFY
$190M
| $1.98K | ﹤0.01% |
+44
| New | +$1.91K |
2026 Q2
0 quarters
|
|
7231
Rain Enhancement Technologies
RAIN
$8.06M
| $1.97K | ﹤0.01% |
950
| – | – |
2025 Q3
3 quarters
|
|
7232
BondBloxx Bloomberg Three Year Target Duration US Treasury ETF
XTRE
$146M
| $1.96K | ﹤0.01% |
40
| – | – |
2025 Q2
4 quarters
|
|
7233
Cryo-Cell International
CCEL
$36.3M
| $1.93K | ﹤0.01% |
605
+4
| +0.7% | +$14 |
2021 Q3
19 quarters
|
|
7234
Adaptive Core ETF
RULE
$17.9M
| $1.93K | ﹤0.01% |
56
+55
| +5,500% | +$1.62K |
2024 Q1
9 quarters
|
|
7235
State Street SPDR Portfolio Treasury ETF
SPTB
$456M
| $1.92K | ﹤0.01% |
64
-77
| -55% | -$2.31K |
2024 Q4
6 quarters
|
|
7236
SoundHound AI Warrant
SOUNW
$161M
| $1.92K | ﹤0.01% |
+1,000
| New | +$2.46K |
2026 Q2
0 quarters
|
|
7237
GQG US Equity ETF
GQGU
$672M
| $1.91K | ﹤0.01% |
75
+5
| +7% | +$131 |
2026 Q1
1 quarter
|
|
7238
GD Culture Group
GDC
$5.37M
| $1.9K | ﹤0.01% |
+924
| New | +$352K |
2026 Q2
0 quarters
|
|
7239
Alaunos Therapeutics
TCRT
$2.67M
| $1.89K | ﹤0.01% |
836
+183
| +28% | +$468 |
2013 Q2
52 quarters
|
|
7240
Namib Minerals
NAMM
$61.4M
| $1.88K | ﹤0.01% |
1,000
-41,921
| -98% | -$79.3K |
2026 Q1
1 quarter
|
|
7241
Vantage Corp
VNTG
$20M
| $1.88K | ﹤0.01% |
3,029
| – | – |
2025 Q4
2 quarters
|
|
7242
SAB Biotherapeutics Warrant
SABSW
$97.5K
| $1.87K | ﹤0.01% |
146,439
| – | – |
2021 Q4
18 quarters
|
|
|
OPNW
7243
OpenWorld, Inc. Common Stock
OPNW
$53.4M
| $1.86K | ﹤0.01% |
303
+3
| +1% | +$22 |
2021 Q3
19 quarters
|
|
7244
ProShares K-1 Free Crude Oil Strategy ETF
OILK
$235M
| $1.85K | ﹤0.01% |
39
-3,174
| -99% | -$175K |
2025 Q2
4 quarters
|
|
7245
Zeo Energy
ZEO
$11.3M
| $1.83K | ﹤0.01% |
2,779
+23
| +0.8% | +$18 |
2025 Q3
3 quarters
|
|
7246
Solitario Resources
XPL
$53.5M
| $1.82K | ﹤0.01% |
2,419
| – | – |
2025 Q3
3 quarters
|
|
7247
Ebang International Holdings
EBON
$11.5M
| $1.81K | ﹤0.01% |
829
-3
| -0.4% | -$7 |
2020 Q3
23 quarters
|
|
7248
Immuron
IMRN
$8.39M
| $1.8K | ﹤0.01% |
1,700
-28,874
| -94% | -$28.8K |
2025 Q2
4 quarters
|
|
7249
USCF Dividend Income Fund
UDI
$3.05M
| $1.8K | ﹤0.01% |
+51
| New | +$1.77K |
2026 Q2
0 quarters
|
|
7250
FT Vest US Equity Enhance & Moderate Buffer ETF September
XSEP
$100M
| $1.78K | ﹤0.01% |
40
| – | – |
2023 Q1
13 quarters
|
|
Similar funds
Morgan Stanley's Q2 2026 Portfolio in Review
As of Q2 2026, Morgan Stanley held 8,715 positions worth $1.89T, up 14% from $1.66T the previous quarter. Its ten largest holdings account for 21% of the portfolio.
Morgan Stanley's Q2 2026 filing shows 425 new, 3,807 increased, 3,215 reduced and 303 closed positions. Its largest new stake was SpaceX: 13,532,773 shares worth $2.31B. The largest sale was State Street SPDR S&P 500 ETF Trust, an estimated $5.96B.
By sector, the portfolio is most concentrated in Miscellaneous at 26% of assets, down from 27% a quarter earlier, followed by Technology and Financials.
- Morgan Stanley's largest Q2 2026 buy was SpaceX: 13,532,773 shares worth $2.31B.
- Morgan Stanley added most to NVIDIA in Q2 2026, an estimated $2.77B increase.
- Morgan Stanley's biggest Q2 2026 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $5.96B.
- Morgan Stanley fully exited Apellis Pharmaceuticals in Q2 2026, selling an estimated $404M.
- Morgan Stanley's ten largest holdings make up 21% of its $1.89T portfolio in Q2 2026.
- Morgan Stanley opened 425 new positions and closed 303 in Q2 2026.
- Morgan Stanley's portfolio value rose 14% quarter-over-quarter to $1.89T.
Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.